Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antiviral, monoclonal antibodies | 5505 | 2423014-07-5 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Sotrovimab is a human IgG1 mAb that binds to a highly conserved epitope on the spike protein receptor binding domain of SARS-CoV-2.
|
| Dose | Unit | Route |
|---|---|---|
| 0.50 | g | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 27, 2021 | PMDA | GLAXOSMITHKLINE K.K. | |
| Dec. 17, 2021 | EMA | GLAXOSMITHKLINE TRADING SERVICES LIMITED |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Infusion related reaction | 184.13 | 39.87 | 92 | 1000 | 416688 | 90210667 |
| COVID-19 pneumonia | 52.99 | 39.87 | 16 | 1076 | 18161 | 90609194 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Infusion related reaction | 146.43 | 41.70 | 55 | 988 | 60751 | 42559541 |
| COVID-19 pneumonia | 64.54 | 41.70 | 23 | 1020 | 21590 | 42598702 |
| Chills | 47.12 | 41.70 | 29 | 1014 | 94037 | 42526255 |
| Oxygen saturation decreased | 45.84 | 41.70 | 25 | 1018 | 64662 | 42555630 |
| Decreased immune responsiveness | 42.74 | 41.70 | 10 | 1033 | 2105 | 42618187 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Infusion related reaction | 305.90 | 37.14 | 151 | 2158 | 381011 | 110205979 |
| COVID-19 pneumonia | 118.84 | 37.14 | 40 | 2269 | 37103 | 110549887 |
| Oxygen saturation decreased | 76.54 | 37.14 | 45 | 2264 | 156937 | 110430053 |
| Decreased immune responsiveness | 54.32 | 37.14 | 16 | 2293 | 9590 | 110577400 |
| COVID-19 | 53.96 | 37.14 | 43 | 2266 | 245017 | 110341973 |
| Chills | 51.98 | 37.14 | 38 | 2271 | 190542 | 110396448 |
| Blood pressure decreased | 38.44 | 37.14 | 26 | 2283 | 115065 | 110471925 |
| Vaccination failure | 37.40 | 37.14 | 9 | 2300 | 2497 | 110584493 |
None
| Source | Code | Description |
|---|---|---|
| ATC | J06BD05 | ANTIINFECTIVES FOR SYSTEMIC USE IMMUNE SERA AND IMMUNOGLOBULINS IMMUNOGLOBULINS Antiviral monoclonal antibodies |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:149553 | anticoronaviral agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| COVID-19 | indication | 840539006 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Spike glycoprotein | Glycoprotein | BINDING AGENT | Kd | 9.68 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| CHEBI:758401 | CHEBI |
| CHEMBL4650524 | ChEMBL_ID |
| C000711967 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11333 | IUPHAR_LIGAND_ID |
| DB16355 | DRUGBANK_ID |
| 1162689008 | SNOMEDCT_US |
| 1162693002 | SNOMEDCT_US |
| 4040549 | VANDF |
| C5433947 | UMLSCUI |
| D12014 | KEGG_DRUG |
| 11766 | INN_ID |
| 346571 | MMSL |
| 39535 | MMSL |
| d09747 | MMSL |
| 018751 | NDDF |
| 1MTK0BPN8V | UNII |
| 2550731 | RXNORM |
None